For today’s episode we will be reviewing three articles from the July-August 2019 issue of Allergy Watch:

Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis

https://www.ncbi.nlm.nih.gov/pubmed/30488542

Allergen content in German cockroach extracts and sensitization profiles to a new expanded set of cockroach allergens determine in vitro extract potency for IgE reactivity

https://www.ncbi.nlm.nih.gov/pubmed/30170124

New IgE immediate hypersensitivity reactions on reintroduction of food restricted for treatment of eosinophilic esophagitis

https://www.ncbi.nlm.nih.gov/pubmed/30684739

Please give us feedback, corrections, and suggestions!

Email feedback to: [email protected]

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:

Dr. Lee was on an advisory board for Teva.

Dr. Kalangara has received consulting fees from AstraZeneca.

Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.